
On Monday, Google DeepMind CEO Demis Hassabis and James Manyika, Senior Vice President of Research, Technology & Society at Google, confirmed a historic milestone for the artificial intelligence community: the AlphaFold Protein Structure Database is now actively powered by over 3 million researchers across 190 countries. This announcement, made during a pivotal interview with Fortune, marks a significant expansion in the democratization of biological research, signaling that AI-driven discovery has moved from a novelty to a fundamental standard in the scientific method.
The update comes alongside the unveiling of a suite of next-generation tools—AlphaGenome, AI Co-scientist, and EarthAI—which collectively promise to reshape how humanity approaches challenges ranging from cancer treatment to climate resilience.
Since its initial release, AlphaFold has solved the 50-year-old "protein folding problem," predicting the 3D structures of nearly all known proteins. The latest data reveals that the tool's reach has expanded far beyond elite institutions in the West.
In the interview, Hassabis emphasized that the 3 million user mark represents a "critical mass" where AI tools are no longer just assisting scientists but are actively compressing centuries of research timelines into mere months.
Building on the success of protein structure prediction, Google DeepMind has officially detailed the capabilities of AlphaGenome, a tool designed to decipher the "software" of life. While AlphaFold focuses on the final product (proteins), AlphaGenome targets the instructions (DNA) and how they are regulated.
Key Technical Capabilities:
James Manyika highlighted that AlphaGenome represents a shift from "reading" the genome to "comprehending" it, potentially unlocking personalized gene therapies that were previously impossible to design.
Perhaps the most radical shift introduced is the AI Co-scientist, a system built on the Gemini 2.0 architecture. Unlike passive search engines or databases, this agentic system actively participates in the scientific process.
The AI Co-scientist is designed to:
In beta tests with academic partners, the AI Co-scientist successfully proposed valid experimental paths for drug repurposing in acute myeloid leukemia, demonstrating high accuracy in distinguishing viable research avenues from dead ends.
Expanding the scope beyond biology, DeepMind also showcased EarthAI, a set of planetary foundation models aimed at climate and environmental challenges. By fusing satellite imagery, weather data, and biological sensors, EarthAI creates a "living map" of the planet.
Core Functions of EarthAI:
The following table outlines the distinct roles and technical foundations of the newly discussed tools:
Tool Name|Primary Domain|Key Technical Feature|Target Outcome
---|---|---
AlphaFold|Protein Biology|Structure prediction from amino acid sequences|Accelerated drug discovery and enzyme engineering
AlphaGenome|Genomics|1 million base-pair context window|Identifying genetic drivers of disease and cancer
AI Co-scientist|General Science|Agentic reasoning via Gemini 2.0|Automated hypothesis generation and experiment design
EarthAI|Environmental Science|Multi-modal planetary data fusion|High-resolution biodiversity tracking and climate resilience
The integration of these tools creates what Hassabis refers to as a "virtuous cycle" of discovery. AlphaGenome identifies a genetic target; AlphaFold predicts the structure of the relevant protein; the AI Co-scientist proposes a drug molecule to interact with it; and EarthAI ensures the sourcing of materials or environmental impact of production is sustainable.
This convergence suggests that 2026 is not just another year of incremental progress, but the beginning of an era where AI is the primary engine of scientific advancement. As these tools become entrenched in the workflows of 3 million researchers, the pace of innovation is expected to accelerate exponentially, fundamentally altering the landscape of healthcare, material science, and environmental protection.